D-0345-2019 Class III Terminated
FDA drug recall D-0345-2019 was initiated by Amerigen Pharmaceuticals Inc. on Dec 20, 2018 and is designated Class III. Reason for recall: Failed Dissolution Specifications The recall status is terminated (terminated Dec 17, 2019). Affected quantity: 771 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 2, 2019
- Initiation Date
- Dec 20, 2018
- Termination Date
- Dec 17, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 771 bottles
Product description
Temozolomide Capsules, 180 mg, packaged in a 14 count bottles, Rx only, Mfd, by: Stason Pharmaceuticals, Inc., Irvine, CA, Dist. By: Amerigen Pharmaceuticals, Lyndhurst, NJ ---- NDC 43975-256-14
Reason for recall
Failed Dissolution Specifications
Distribution pattern
Product was distributed to 4 wholesalers and 2 retail accounts who may have further distributed the products.
Code information
Lot # 18E031, exp 05/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0345-2019
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026